SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, amplified by SOXLs 3x daily leverage, has fueled attention; LAM Researchs warning about component supply constraints added to concerns around AI-chip demand and heavy AI spending. Traders are divided between viewing the drop as an oversold washout and expecting further losses, while debating whether semiconductor and AI growth remains intact or is being repriced.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Mercks Keytruda, released after a data leak, are driving attention: traders note the results showed lower recurrence risk but argue they fell short of expectations built into the stocks steep run-up, prompting a sharp selloff. The community is split between viewing the drop as a sell-the-news overreaction to positive data and seeing it as a valuation reset, with intense debate over the vaccines commercial potential and the stocks next move.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook were met with a sharp selloff, with traders debating whether heavy capital spending, negative cash flow and a rich valuation outweigh the companys growth prospects. Some blame broader pressure on AI-related stocks, while bullish traders view the decline as an overreaction to results they consider strong.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

A steep pullback from recent highs is dominating discussion, with traders pointing to broader market and sector selling alongside higher oil and jet-fuel costs amid Middle East tensions. Some see the companys fundamentals and share buybacks as reasons to stay bullish, while others question the weakness and warn of further downside.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPEs sharp rebound and gains alongside a broader meme-coin rally are driving attention, with traders cheering for another leg higher. Others question the moves staying power, pointing to thin volume, repeated resistance, and choppy consolidation; no specific news catalyst is established.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly update has drawn attention after revenue missed expectations and management cut its sales outlook amid price-conscious shoppers and heavier footwear promotions, despite raising earnings guidance. Traders are divided between viewing the selloff as an overreaction given profitability and buybacks, and focusing on weaker growth and the cautious outlook.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff and fresh lows are being tied by traders to plans to explore a separate listing for fintech unit Monee and launch Sea Cloud, raising concerns about spending, execution and how a listing could affect existing shareholders. Some see Monee as a source of potential value, while others view the plans as added uncertainty amid a severe technical downturn.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Bullish analyst initiations are drawing attention to Celcuitys commercial opportunity for FDA-approved REVTORPYK, with traders also highlighting a potential PIK3CA-mutant label expansion. Optimism about the drugs market potential is balanced by debate over whether the early launch can translate into meaningful prescription and revenue growth.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks are under pressure after LAM Researchs CEO warned that component supply constraints could persist into 2027, prompting a broad chip-sector selloff. Traders are split between viewing the decline and tests of key support as an oversold buying opportunity and warning that weakening AI sentiment and continued lower highs point to more downside.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat outlook were met with a sharp share decline, prompting traders to debate whether the selloff reflects a broader retreat from AI-linked stocks or concerns about higher capital spending and a potentially cyclical peak outweighing robust storage demand. Some see the reaction as an overdone sell-the-news move, while others question how durable current growth and pricing will be.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape

From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating   New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of replacing damaged or lost insulin-producing cells sounded more like a long-term scientific goal than a practical treatment strategy. That is […]
The post Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape appeared first on Financial News Media.

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin...

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences Lakewood-Amedex Biotherapeutics Announces Participation in October ConferencesPR NewswireSARASOTA, Fla., Oct. 1, 2026SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the...

LABT’s Nu-3 Takes Aim at Resistant Foot Infections as Phase 2 Catalyst Looms

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is heading deeper into the clinical stage with its lead antimicrobial candidate Nu-3, and fresh laboratory data are giving the company another potential catalyst as its Phase 2a trial gets underway.

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 28, 2026 Lead...

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 24...

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3PR NewswireSARASOTA, Fla., Sept. 21...

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of...

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SARASOTA, Fla., Sept. 8, 2026 SARASOTA, Fla., Sept. 8, 2026 /PRNewswire...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
Lakewood-Amedex (NASDAQ:LABT)read more...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.</li><li>This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers.</li><li>Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.</li></ul>Shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) soared more than 70% in Friday’s pre-market trade, a day after the company announced a direct listing on the Nasdaq stock exchange.Lakewood-Amedex Biotherapeutics began trading on the Nasdaq on Thursday, closing the day up over 8% and with a market capitalization of $122 million.<a href="https://stocktwits.com/symbol/LABT">Lakewood-Amedex Biotherapeutics shares</a> were up nearly 50% in Friday’s pre-market trade.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory, with message volumes at ‘extremely high’ levels. LABT was among the top-trending tickers on the platform at the time of writing.One user stated that the real test for LABT would be how it handles the $14 level on any pullback today would be the real test for the stock.<stembedurl>https://stocktwits.com/Olivia_Strickland/message/651253709</stembedurl><h2 class="st-heading-2">Chairman Says Listing Will Accelerate Development</h2>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers (iDFU).Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.Cooper added that of the 40 million diabetes patients in the U.S., around one-third develop DFU in their lifetime. He stated that the DFU will become infected in around half of these patients.“Numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need,” Cooper added.<h2 class="st-heading-2">Early Exploratory Trials Showed No Safety Concerns, Says Company</h2>The company stated that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns, while indicating a trend toward antimicrobial activity and improved wound healing.Based on these findings, the company plans to initiate a Phase 2a study to assess safety and dose response, followed by a placebo-controlled Phase 2b trial comparing different doses.The program will also evaluate the optimal administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers, the company said.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

Lakewood-Amedex Biotherapeutics started trading on the Nasdaq on Thursday, closing the day with gains of over 8% and a market capitalization of $122 million.

LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$0.4895
Prev Close	$0.466
Open	$0.4665
Dividend Yield	N/A
50-Day Moving Average	$1.63
Beta	0.42
Avg. Volume	2.33M
PE Ratio	-0.05

52-Week High	$98.20
52-Week Low	$0.4216
Market Capitalization	$1.16M
EPS (Annual)	-$8.40
Price to Book	0.25
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

LABT Fundamentals